These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
395 related articles for article (PubMed ID: 26725479)
1. Calcium signaling in human stem cell-derived cardiomyocytes: Evidence from normal subjects and CPVT afflicted patients. Zhang XH; Morad M Cell Calcium; 2016 Mar; 59(2-3):98-107. PubMed ID: 26725479 [TBL] [Abstract][Full Text] [Related]
2. Ca2+ signaling in human induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects. Zhang XH; Haviland S; Wei H; Sarić T; Fatima A; Hescheler J; Cleemann L; Morad M Cell Calcium; 2013 Aug; 54(2):57-70. PubMed ID: 23684427 [TBL] [Abstract][Full Text] [Related]
3. Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations. Kujala K; Paavola J; Lahti A; Larsson K; Pekkanen-Mattila M; Viitasalo M; Lahtinen AM; Toivonen L; Kontula K; Swan H; Laine M; Silvennoinen O; Aalto-Setälä K PLoS One; 2012; 7(9):e44660. PubMed ID: 22962621 [TBL] [Abstract][Full Text] [Related]
4. Calcium signaling consequences of RyR2 mutations associated with CPVT1 introduced via CRISPR/Cas9 gene editing in human-induced pluripotent stem cell-derived cardiomyocytes: Comparison of RyR2-R420Q, F2483I, and Q4201R. Zhang XH; Wei H; Xia Y; Morad M Heart Rhythm; 2021 Feb; 18(2):250-260. PubMed ID: 32931925 [TBL] [Abstract][Full Text] [Related]
6. A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses. Preininger MK; Jha R; Maxwell JT; Wu Q; Singh M; Wang B; Dalal A; Mceachin ZT; Rossoll W; Hales CM; Fischbach PS; Wagner MB; Xu C Dis Model Mech; 2016 Sep; 9(9):927-39. PubMed ID: 27491078 [TBL] [Abstract][Full Text] [Related]
7. Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations. Novak A; Barad L; Lorber A; Gherghiceanu M; Reiter I; Eisen B; Eldor L; Itskovitz-Eldor J; Eldar M; Arad M; Binah O J Cell Mol Med; 2015 Aug; 19(8):2006-18. PubMed ID: 26153920 [TBL] [Abstract][Full Text] [Related]
8. Mutation-specific differences in arrhythmias and drug responses in CPVT patients: simultaneous patch clamp and video imaging of iPSC derived cardiomyocytes. Pölönen RP; Swan H; Aalto-Setälä K Mol Biol Rep; 2020 Feb; 47(2):1067-1077. PubMed ID: 31786768 [TBL] [Abstract][Full Text] [Related]
9. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells. Itzhaki I; Maizels L; Huber I; Gepstein A; Arbel G; Caspi O; Miller L; Belhassen B; Nof E; Glikson M; Gepstein L J Am Coll Cardiol; 2012 Sep; 60(11):990-1000. PubMed ID: 22749309 [TBL] [Abstract][Full Text] [Related]
10. Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia. Sasaki K; Makiyama T; Yoshida Y; Wuriyanghai Y; Kamakura T; Nishiuchi S; Hayano M; Harita T; Yamamoto Y; Kohjitani H; Hirose S; Chen J; Kawamura M; Ohno S; Itoh H; Takeuchi A; Matsuoka S; Miura M; Sumitomo N; Horie M; Yamanaka S; Kimura T PLoS One; 2016; 11(10):e0164795. PubMed ID: 27764147 [TBL] [Abstract][Full Text] [Related]
11. Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC Models. Penttinen K; Swan H; Vanninen S; Paavola J; Lahtinen AM; Kontula K; Aalto-Setälä K PLoS One; 2015; 10(5):e0125366. PubMed ID: 25955245 [TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9 Gene Editing of RYR2 in Human iPSC-Derived Cardiomyocytes to Probe Ca Yamaguchi N; Zhang XH; Morad M Methods Mol Biol; 2022; 2573():41-52. PubMed ID: 36040585 [TBL] [Abstract][Full Text] [Related]
13. In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells. Fatima A; Xu G; Shao K; Papadopoulos S; Lehmann M; Arnáiz-Cot JJ; Rosa AO; Nguemo F; Matzkies M; Dittmann S; Stone SL; Linke M; Zechner U; Beyer V; Hennies HC; Rosenkranz S; Klauke B; Parwani AS; Haverkamp W; Pfitzer G; Farr M; Cleemann L; Morad M; Milting H; Hescheler J; Saric T Cell Physiol Biochem; 2011; 28(4):579-92. PubMed ID: 22178870 [TBL] [Abstract][Full Text] [Related]
14. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. Jung CB; Moretti A; Mederos y Schnitzler M; Iop L; Storch U; Bellin M; Dorn T; Ruppenthal S; Pfeiffer S; Goedel A; Dirschinger RJ; Seyfarth M; Lam JT; Sinnecker D; Gudermann T; Lipp P; Laugwitz KL EMBO Mol Med; 2012 Mar; 4(3):180-91. PubMed ID: 22174035 [TBL] [Abstract][Full Text] [Related]
15. Slowed depolarization and irregular repolarization in catecholaminergic polymorphic ventricular tachycardia: a study from cellular Ca2+ transients and action potentials to clinical monophasic action potentials and electrocardiography. Paavola J; Väänänen H; Larsson K; Penttinen K; Toivonen L; Kontula K; Laine M; Aalto-Setälä K; Swan H; Viitasalo M Europace; 2016 Oct; 18(10):1599-1607. PubMed ID: 26705554 [TBL] [Abstract][Full Text] [Related]